Structure Therapeutics Inc
Research Structure Therapeutics Inc (GPCR) on Bullrun: market cap USD 3.55B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerGPCR
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 3.55B
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 106.16M
- Free cash flow-USD 120.07M
Valuation Snapshot
latest market cap is USD 3.55B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 141.20M | -USD 225.81M | n/a | -0.8 | USD 799.62M | USD 6.49M | USD 1.52B |
| FY2024 | USD 0 | -USD 122.53M | -USD 117.93M | n/a | -0.78 | USD 169.51M | USD 3.86M | USD 864.84M |
| FY2023 | n/a | -USD 89.62M | -USD 81.66M | n/a | -0.81 | USD 129.79M | USD 5.45M | USD 452.97M |
| FY2022 | n/a | -USD 51.32M | -USD 46.28M | n/a | -5.51 | USD 26.09M | n/a | -USD 115.14M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 3.55B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 4.93B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 1.55B | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 1.89B | n/a | n/a | n/a |
About Structure Therapeutics Inc
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Structure Therapeutics Inc's market cap?
Structure Therapeutics Inc's market capitalization is USD 3.55B.
What does Structure Therapeutics Inc do?
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions.